News
TipRanks on MSN2d
Septerna Begins Phase 1 Trial for SEP-631
The latest announcement is out from Septerna, Inc. ( (SEPN) ).
(Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced the dosing of the first participants in its Phase 1 ...
TipRanks on MSN2d
Septerna doses first participants in Phase 1 trial of SEP-631
Septerna (SEPN) announced the dosing of the first participants in its Phase 1 clinical trial of SEP-631, a selective oral small molecule ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback